Calliditas Therapeutics IPO Presentation Deck
IgAN in the U.S. - significant unmet medical need with considerable cost to
society
Market size and patient profile
Total market opportunity of $9-10 billion in the
U.S. alone
Prevalence of 130,000 - 150,000
Normally presents when patient in their 20-30s
More prevalent in men than in women
Up to 50% at risk of developing ESRD within 10-
20 years
ESRD cost to society
Dialysis can cost between $70,000 and $200,000 per year,
with a total estimated annual hemodialysis cost in the U.S. of
$42 billion ¹.2
Kidney transplant average cost $414,800³ with a total
estimated annual cost in the U.S. of $7 billion
Source: 1) U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD,
2014. 2) Calliditas estimate based on interviews commissioned by the Company. 3) Milliman, Milliman research report:2017 U.S organ and tissue and transplant cost estimation and discussion.
calliditas
June 2020
22View entire presentation